(0.03%) 5 072.11 points
(-0.06%) 38 482 points
(0.10%) 15 712 points
(-0.50%) $82.94
(-9.33%) $1.643
(-0.31%) $2 334.90
(-0.29%) $27.28
(-0.95%) $914.00
(-0.02%) $0.934
(0.69%) $10.98
(-0.10%) $0.802
(-0.97%) $92.28
Live Chart Being Loaded With Signals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally...
Stats | |
---|---|
Today's Volume | 106 329 |
Average Volume | 140 243 |
Market Cap | 751.41M |
EPS | $0 ( 2024-02-21 ) |
Last Dividend | $0.0500 ( 2023-09-05 ) |
Next Dividend | $0 ( N/A ) |
P/E | 26.30 |
ATR14 | $0.0210 (0.14%) |
Volume Correlation
Clinuvel Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Clinuvel Pharmaceuticals Correlation - Currency/Commodity
Clinuvel Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $78.32M |
Gross Profit: | $50.59M (64.59 %) |
EPS: | $0.620 |
Q2 | 2024 |
Revenue: | $32.26M |
Gross Profit: | $16.92M (52.46 %) |
EPS: | $0.220 |
Q4 | 2023 |
Revenue: | $48.97M |
Gross Profit: | $33.49M (68.40 %) |
EPS: | $0.390 |
Q3 | 2022 |
Revenue: | $24.48M |
Gross Profit: | $22.35M (91.31 %) |
EPS: | $0.190 |
Financial Reports:
No articles found.
Clinuvel Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0400 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.0500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0200 | 2018-09-21 |
Last Dividend | $0.0500 | 2023-09-05 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | $0.185 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.16 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.96 | |
Div. Directional Score | 8.66 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RWC.AX | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
CAJ.AX | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
LSF.AX | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
TAH.AX | Ex Dividend Junior | 2023-08-31 | Annually | 0 | 0.00% | |
CSR.AX | Ex Dividend Knight | 2023-05-26 | Annually | 0 | 0.00% | |
NCM.AX | Ex Dividend Knight | 2023-10-18 | Semi-Annually | 0 | 0.00% | |
WPR.AX | Ex Dividend Junior | 2023-06-29 | Quarterly | 0 | 0.00% | |
FAR.AX | No Dividend Player | 2023-08-23 | Sporadic | 0 | 0.00% | |
PL8.AX | Ex Dividend Knight | 2023-09-14 | Monthly | 0 | 0.00% | |
APE.AX | Ex Dividend Junior | 2023-09-01 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.371 | 1.500 | 2.58 | 3.86 | [0 - 0.5] |
returnOnAssetsTTM | 0.142 | 1.200 | 5.25 | 6.30 | [0 - 0.3] |
returnOnEquityTTM | 0.176 | 1.500 | 9.16 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.0819 | -1.000 | 9.18 | -9.18 | [0 - 1] |
currentRatioTTM | 6.86 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.38 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.321 | 1.500 | 3.77 | 5.66 | [0.2 - 2] |
debtRatioTTM | 0.00168 | -1.500 | 9.97 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.843 | 2.00 | 9.72 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.725 | 2.00 | 9.64 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00199 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.621 | 1.000 | 2.99 | 2.99 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.483 | 1.000 | 2.33 | 2.33 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 118.80 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.384 | 0.800 | -0.775 | -0.620 | [0.5 - 2] |
Total Score | 10.36 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.92 | 1.000 | 7.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.176 | 2.50 | 9.46 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.725 | 2.00 | 9.76 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.334 | 1.500 | 1.661 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.843 | 2.00 | 9.72 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.0819 | 1.500 | 9.18 | -9.18 | [0 - 1] |
pegRatioTTM | 1.047 | 1.500 | 6.36 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.520 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.96 |
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators